These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 8237943)
1. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968 [TBL] [Abstract][Full Text] [Related]
3. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study. De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228 [TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Fujii T; Obara T; Tanno S; Ura H; Kohgo Y Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987 [TBL] [Abstract][Full Text] [Related]
5. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis. Kinnby B; Matsson L; Lecander I Scand J Dent Res; 1994 Dec; 102(6):334-41. PubMed ID: 7871356 [TBL] [Abstract][Full Text] [Related]
6. Factors involved in the plasminogen activation system in human breast tumours. Damjanovich L; Turzó C; Adány R Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332 [TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Gris JC; Schved JF; Marty-Double C; Mauboussin JM; Balmes P Chest; 1993 Jul; 104(1):8-13. PubMed ID: 7686838 [TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]. Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766 [TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706 [TBL] [Abstract][Full Text] [Related]
12. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits. Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381 [TBL] [Abstract][Full Text] [Related]
13. The expression of plasminogen activator system in a rat model of periodontal wound healing. Xiao Y; Li H; Bunn C; Bartold PM J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395 [TBL] [Abstract][Full Text] [Related]
15. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385 [TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981 [TBL] [Abstract][Full Text] [Related]
17. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726 [TBL] [Abstract][Full Text] [Related]
18. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092 [TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Offersen BV; Pfeiffer P; Andreasen P; Overgaard J Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889 [TBL] [Abstract][Full Text] [Related]
20. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]